Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-06-12
2007-06-12
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C436S518000, C436S501000, C530S388100, C435S326000
Reexamination Certificate
active
10488774
ABSTRACT:
The present invention provides a monoclonal antibody designated SM047 against cancer, specifically ovarian carcinoma. SM047 is strongly expressed in most ovarian serous adenocarcinomas and in other female genital tract adenocarcinomas. The monoclonal antibody according to the invention is useful to detect a cancer, specifically ovarian carcinoma and/or or determine the origin of cancer. The present invention also provides a hybridoma cell producing the monoclonal antibody and an antigen which binds to the monoclonal antibody according to the present invention.
REFERENCES:
patent: WO 88/03954 (1988-06-01), None
patent: WO 89/01629 (1989-02-01), None
Sell, Stem cell origin of cancer and differntiation therapy. Critical Reviews in Oncology/Hematology, vol. 51, pp. 1-28, Jul. 2004.
Cho & Leahy, Structure of the extracellular region of HER3 reveals an interdomain tether, Aug. 2002, Science vol. 297, ages 1330-1333, with commentary by Patrice Pages.
Piek et al., Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstetrics Gynecol vol. 191, pp. 718-732, Sep. 2004.
Roitt, et al., Immunology, 6th Edition, Jun. 2001, pp. 65-85.
McCluggage, Recent advances in immunohistochemistry in the diagnosis of ovarianneoplasm F. Clin Pathol, 2000, vol. 53, pp. 327-334.
Kurosaka et al., Production of monoclonal antibodies recognizing cancer-associated antigens expressed on mucin-type sugar chains. Biochem Biophys Res comm, vol. 203, No. 3, pp. 1828-1834. Sep. 1994.
McCluggage et al, monoclonal antibody SM047 as an immunohistochemical marker of ovarian adenocarcinoma. 2001. Histopathology vol. 38, 542-549.
Bell, Origins and molecular pathology of ovarian cancer. 2005. Modern Pathology vol. 18, pp. S19-S32.
Kurosaka et al., “Production of Monoclonal Antibodies, Recognizing Cancer-Associated Antigens Expressed on Mucin-Type Sugar Chains”, Biochemical and Biophysical Research Communications, Vo. 203, No. 3, pp. 1828-1834, Sep. 30, 1994.
McCluggage et al., “Monoclonal antibody SM047 as an immunohistochemical marker of ovarian adencarcinoma”, Histopathology 2001, 38, 542-549.
McCluggage, “Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms”, F. Clin. Pathol. 2000; 53:327-334.
Cheung et al., “Is Immunostaining With HAM56 Antibody Useful in Identifying Ovarian Origin of Metastatic Adencarcinomas?”, Huamn Pathology, vol. 28, No. 1, pp. 91-94, Jan. 1997.
Loy et al., “Distribution of CA 125 in Adencarcinomas”, A.J.C.P., Aug. 1992, pp. 175-179.
Wauters et al., “Keratins 7 and 20 as Diagnostic Markers of Carcinomas Metastatic to the Ovary”, Human Pathology, vol. 26, No. 8, pp. 852-855, Aug. 1995.
Berezowski et al., “Cytokeratins 7 and 20 and Carcinoembryonic Antigen in Ovarian and Colonic Carcinoma”, Modern Pathology, pp. 426-429.
Golombick et al. , “Establishment and Characterization of Two New Human Ovarian Cancer Cell Lines . . . ”, Cell. Dev. Biol. 26:447-454, May 1990.
Warren et al., “Membranes of Animal Cells”, J. Cell. Physiol., 68:269-288.
Veenstra et al., “Multi-well cell monolayers for immunocytochemistry”, Journal of Immunological Methods, 146 (1992), pp. 257-258.
Jones, “Analysis of Radiolabeled Lymphocyte Proteins by One- and Two-Dimensional Polyacrylamide Gel Electrophoresis”, pp. 398-440.
Bayer et al., “Analysis of Proteins and Glycoproteins on Blots”, Methods in Enzymology, Vol. 184, pp. 415-427.
Biosynthetic Labelling of Proteins, Current Protocols in Immunology, Unit 8.12.1-8.12.9.
Young et al., “Metastases from Carcinomas of the Pancreas Simulating Primary Mucinous Tumors of the Ovary”, The American Journal of Surgical Pathology, 13(9); pp. 748-756, 1989.
Jacobs et al., “Clinical Review: The CA 125 tumour-associated antigen: a review of the literature”, Human Reproduction, vol. 4, No. 1, pp. 1-12, 1989.
Nouwen et al., “Immunohistochemical Localization of Placental Alkaline Phorphatase, Carcinoembryonic Antigen, . . . ”, Cancer Research, vol. 46, Feb. 1986, pp. 886-876.
Fick Catharina E.
Veenstra Hannelore F. U.
Schulman B. Aaron
Stellenbosch University
Stites & Harbison PLLC
The Medical Research Council
Yu Misook
LandOfFree
Monoclonal antibody against ovarian carcinoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibody against ovarian carcinoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibody against ovarian carcinoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3852294